Skip to content

Climb Bio, Inc. CLYM Operating lease liabilities

Operating lease liabilities at other companies

Vera Therapeutics logo
Vera TherapeuticsVERA
Kyverna Therapeutics, Inc. logo
Kyverna Therapeutics, Inc.KYTX
Jade Biosciences, Inc. Common Stock logo
Jade Biosciences, Inc. Common StockJBIO
Shattuck Labs, Inc. logo
Shattuck Labs, Inc.STTK
Alumis Inc. logo
Alumis Inc.ALMS
Vor Biopharma logo
Vor BiopharmaVOR

Other financials

Income statement

See full
Operating income-$15.2M+33.9%
Net income-$13.7M+34.0%
EPS (diluted)-$0.20+35.5%

Balance sheet

See full
Cash & equivalents$8.4M-71.2%
Total debt$479.0K+1.1%
Total equity$148.1M-23.4%
Total assets$152.4M-24.1%

Cash flow

See full
Operating cash flow-$14.4M+6.8%
CapEx$109.0K
Free cash flow-$15.6M-183%

Valuation

See full
Market cap$724.95M+787%
Enterprise value$717.07M+1,247%

Returns & leverage

See full
Return on equity-30.9%-10.3pp
Debt / equity0.0×
Current ratio27.9×+13.6×

Where this comes from

Reported directly by Climb Bio, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOperatingLeaseLiability.

The official record: Climb Bio, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Climb Bio, Inc.'s operating lease liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Climb Bio, Inc.'s operating lease liabilities?
Climb Bio, Inc. (CLYM) reported operating lease liabilities of -$62K in Q1 2026.
How has Climb Bio, Inc.'s operating lease liabilities changed year-over-year?
Climb Bio, Inc.'s operating lease liabilities decreased by 5.1% year-over-year, from -$59K to -$62K.
What is the long-term trend for Climb Bio, Inc.'s operating lease liabilities?
Over 3 years (2022 to 2025), Climb Bio, Inc.'s operating lease liabilities has grown at a -54.2% compound annual growth rate (CAGR), from -$447K to $43K.